S&P Futures
4,167.25-9.00(-0.22%)Dow Futures
34,023.00-58.00(-0.17%)Nasdaq Futures
13,967.50-62.00(-0.44%)
Karyopharm Therapeutics Inc. (KPTI)
9.71 0.00 (0.00%)
Pre-Market: 8:12AM EDT
Chart Events
Performance Outlook
| Previous Close | 9.69 |
| Open | 9.66 |
| Bid | 9.60 x 1800 |
| Ask | 9.70 x 800 |
| Day's Range | 9.55 - 9.95 |
| 52 Week Range | 9.53 - 25.98 |
| Volume | 1,403,048 |
| Avg. Volume | 2,525,700 |
| Market Cap | 728.847M |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.72 |
| Earnings Date | May 03, 2021 - May 07, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
Fair Value
Related Research
- PR Newswire
Karyopharm Announces Publication of Health-Related Quality of Life Outcomes from Phase 3 SEAL Study of Selinexor in Advanced Unresectable Dedifferentiated Liposarcoma in Future Oncology
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-related quality of life (HRQoL) data from the Phase 3 portion of the SEAL (Selinexor in Advanced Liposarcoma) study were published online in Future Oncology. The SEAL study evaluated twice weekly, single agent selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, versus matching placebo in patients with advanced unresectable dedifferentiated liposarcoma (DDLPS) who have experienced disease progression following at least two prior therapies. XPOVIO® (selinexor) is currently approved by the U.S. Food & Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma and relapsed or refractory diffuse large B-cell lymphoma; XPOVIO has not been approved for the treatment of DDLPS and, therefore, its safety and efficacy for that patient population have not been established.
- Simply Wall St.
Market Sentiment Around Loss-Making Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
We feel now is a pretty good time to analyse Karyopharm Therapeutics Inc.'s ( NASDAQ:KPTI ) business as it appears the...
- Benzinga
Karyopharm Stock Is Trading Higher After China's NMPA Signs Off Early-Stage ATG-019 Study In Cancer Settings
The National Medical Products Administration (NMPA) has approved Antengene Corporation Limited's Investigational New Drug Application for a Phase 1 trial of ATG-019 in China. The trial will evaluate the safety and tolerability of ATG-019 (monotherapy or combined with niacin ER) in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL). ATG-019 is a dual PAK4/NAMPT inhibitor developed by Karyopharm Therapeutics Inc (NASDAQ: KPTI). Antengene reached an exclusive agreement with Karyopharm and obtained the exclusive development and commercialization rights of ATG-019 in Greater China, South Korea, Australia, New Zealand, and ASEAN countries. Antengene is conducting a Phase 1 trial of ATG-019 in Taiwan in patients with advanced NHL and solid tumors and is planning to conduct clinical trials exploring its combination potential with other agents. Price Action: KPTI shares are up 4.95% at $11.66 in the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaKaryopharm's Selinexor Receives Conditional Approval In Europe For Type Of Blood Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
